A prospective phase 11 study was performed to determine the feasibility and efficacy in terms of response rate, resectability, and morbidity in patients with locally advanced rectal cancer who received preoperative regional hyperthermia combined with radiochemotherapy (HRCT).
Objective
A prospective phase 11 study was performed to determine the feasibility and efficacy in terms of response rate, resectability, and morbidity in patients with locally advanced rectal cancer who received preoperative regional hyperthermia combined with radiochemotherapy (HRCT).
Summary Background Data
Recent studies suggest that preoperative radiochemotherapy in locally advanced rectal cancer can induce downstaging, but after resection the incidence of local recurrences remains high. Hyperthermia (HT) may add tumoricidal effects and improve the efficacy of radiochemotherapy in a trimodal approach.
Patients and Methods
Thirty-seven patients with histologically proven rectal cancer and T3 or T4 lesions, as determined by endorectal ultrasound and computed tomography, entered the trial. 5-Fluorouracil (300-350 mg/M2) and leucovorin (50 mg) were administered on days 1 to 5 and 22 to 26 . Regional HT using the SIGMA 60 applicator (BSD-2000) was given once a week before radiotherapy (45 Gy with 1 .8-Gy fractions for 5 weeks). Surgery followed 4 to 6 weeks after completion of HRCT.
Results
Preoperative treatment was generally well tolerated, with 16% of patients developing grade Ill toxicity. No grade IV complications were observed. The overall resectability rate was 32 of 36 patients (89%), and 31 resection specimens had negative margins (RO). One patient refused surgery. In 5 patients (14%), the histopathologic report confirmed no evidence of residual tumor (pCR). A partial remission (PR) was observed in 17 patients (46%). The survival rate after 38 months was 86%. In none of the patients was local recurrence detected after R0(L), but five patients developed distant metastases.
Conclusion
Preoperative HRCT is feasible and effective and may contribute to locoregional tumor control of advanced rectal cancer, which is to be proven in an ongoing phase Ill trial.
In rectal cancer, resection with negative margins is the major tool for achieving long-term survival. However, in locally advanced tumors (UICC stages II and HI), local recurrences after surgery alone have been reported in up to 58% of patients.1'2 For recurrent rectal cancer, the prognosis is poor. 3'4 Efforts to improve the treatment results of stage Ill tumors further focus on preoperative radiotherapy or combined radiochemotherapy. The rationale is: 1) to irradiate the tumor in a well-oxygenated status7'8; 2) to prevent tumor cell seeding during surgery; 3) to reduce radiotherapyrelated small-bowel toxicity9; and 4) 
PATIENTS AND METHODS Study Design
Thirty-seven patients with locally advanced primary rectal cancer and a biopsy-proven adenocarcinoma were entered into the study (Table 1) . They all presented with tumor infiltration beyond the rectal wall at endorectal ultrasound (ERUS) and computed tomography (CT) scan and were subjected to combined modality therapy (Fig. 1 ). Four to six weeks after completion of preoperative treatment, restaging was accomplished, and all patients were scheduled for laparotomy. If an RO resection could be achieved, four cycles of adjuvant chemotherapy were administered postopera- 
RESULTS

Toxicity During Preoperative Treatment
Thirty patients completed preoperative hyperthermia combined with radiochemotherapy (HRCT) according to the protocol. There were no deaths (related or unrelated to treatment preoperatively) during the first 3 months after the start of treatment. Therapy had to be stopped in 1 patient who developed diarrhea after receiving 41.5 Gy of radiotherapy; 32 of 37 patients received all scheduled HT sessions. One patient refused further HT after the first session because of general discomfort, another two patients because of claustrophobia. HT was abandoned in another patient after three sessions due to local complaints and in one patient for cardiac rhythm disorders.
Adverse reactions were observed starting during week 3 of therapy. They were mostly related to the small bowel and rectum (diarrhea, crampmg, proctitis). A second aspect of complaints arose from the skin, particularly the rima ani (ery- Table 3 , the toxicity of HT was within the same range as that of chemo-or radiotherapy.
Late toxicity, such as chronic bowel dysfunction, ulcerations of the rectum or bladder, or obstruction or stricture of the ureter, has not yet been observed. Sexual dysfunction was documented in 2 of the 31 male patients (erectility, ejaculation) and 1 of the 6 female patients (dyspareunia).
One adverse event that might be associated with late toxicity occurred in a 60-year-old patient who presented with a uT4 tumor invading the prostate with progression after preoperative treatment. Laparotomy confirmed that it was nonresectable, and radiochemotherapy was completed up to 61 Gy. Five months later, he presented with septicemia because of perforation of the rectum. We could not differentiate exactly between tumor-related necrosis or treatment-induced tissue damage.
Surgery and Perioperative Morbidity
Thirty-six patients underwent laparotomy. One patient refused surgery after completion of HRTC. In this patient the tumor distance from the anal verge was 2 cm, and the tumor size did not change by ERUS and CT. In 32 patients (86.5%), the primary tumor was resected. In 4 patients (10.8%), the tumor was found to be nonresectable due to fixation to the lateral pelvis or the prostate, and a colostomy was performed. Thirty-one resection specimens (96.9%) had negative histologic margins. Another two patients (in addition to those with already known liver metastases) were found to have liver lesions at laparotomy; one of them subsequently underwent a liver resection.
Surgical treatment resulted in a sphincter-preserving procedure in 19 of 37 patients (51%). Besides anterior resection, in three patients a colonic pouch with a pouch-anal anastomosis was performed. Another two patients had a sphincter-saving procedure by transanal full-layer resection ( Table 4) .
The median blood loss was 860 mL per patient (range 200-2000 mL per patient). Homologous blood transfusions were necessary in 9 patients, with a median of 2.2 units per patient (range 1-4 units per patient). There was no mortality within 90 days postoperatively. Complications included two patients with anastomotic leakages. One patient required reintervention and a colostomy had to be performed; the other one could be treated conservatively. Seven patients had delayed wound healing, one relating to the abdomen and six to the perineal wound after an abdominoperineal excision, which responded to local wound care. Two patients developed pneumonia and required antibiotic treatment. Cardiac abnormalities were recorded in one patient with a heart rhythm disorder, with complete resuscitation after medical therapy. 
Evaluation of Response
In Figure 2 , the depth of tumor infiltration into the rectal wall, as measured by pretherapeutic ERUS, is compared to the histologic findings in the 32 patients who underwent resection. We found downstaging in 17 of 32 patients (53%); in particular, organ infiltration of uT4 tumors was present before HRCT in 10 patients and could be detected after treatment in only 2 patients. Less infiltration was observed in 9 of the 23 patients with uT3 tumors.
However, after preoperative treatment, ERUS (yuT at restaging) classified the T category correctly as compared with the histopathologic reappraisal in only 50% (16/32) of the cases. In 14 patients, ERUS suggested a higher T category than found at histopathology; in 2 patients, tumor infiltration at histology was deeper than predicted by ERUS.
Before HRCT, 21 patients were classified as having tumor in the lymph nodes, and 18 of them underwent resection. Of those, the histopathologic report revealed 8 specimens with node-negative tumors (ypNO, response rate 44%).
In five resection specimens, no residual tumor could be detected at histology, resulting in a pCR rate of 13.5%.
Another 17 specimens showed downstaging of uT versus ypT or a 50% decrease in tumor size, as documented by CT or ERUS, resulting in a PR rate of 45.9%. Thus, the overall response rate was 59.4% (Table 5) .
Response Analysis
As shown in 
Follow-Up and Survival
The overall survival rate of 37 patients was 56%. After a median observation period of 21 months, 27 patients with RO tumor resection showed an actuarial survival of 86% at 38 months (Fig. 3) Primary nonresectable and recurrent rectal tumors, some of which had already been irradiated, were subjected to HT using a capacity system (Thermotron, Yamamoto Vinyter Co., Osaka, Japan) or microwave applicators (433-MHz lens applicator). 23 The response rate of 54% determined by CT and the local control rate of 28% after 12 months were higher than in the group treated with radiation alone (36% and 22%, respectively) but failed to reach significance.
In the phase II study presented here, regional radiowave HT with a phased-array system was used in addition to radiochemotherapy, which is the standard preoperative treatment for advanced rectal cancer. The antenna system allows heat distribution to be influenced so discriminate between tumor invasion and attachment because of inflammatory reaction. ERUS confirms with high diagnostic accuracy the extent of tumor invasion beyond the rectal wall. In untreated rectal cancer, the diagnostic accuracy of ERUS for the T categories is 87%47; therefore, ERUS was used to assess the eligibility of patients. Consequently, the downstaging rate of 59% achieved in our study might be even more valuable compared to trials omitting pretherapeutic endosonography as a basis for entering patients in the study. However, the accuracy of ERUS is lowered after HRCT: only 50% of the specimens were correctly staged for depth of wall penetration and 59% tumor-occupied lymph nodes. The underlying reasons may be edema formation and the difficulty in differentiating between intratumoral fibrosis and infiltration of the rectal wall. This phenomenon has also been described after radiochemotherapy.48
In our series, the response rate was 59.4%, with 14% complete remissions. A further 37% of the resection specimens had residual disease as small remnants and were staged as ypT2 or less. Our results seem to show improved effects of HRCT compared to radiotherapy alone or radiochemotherapy ( Table 7) . The high proportion of fixed and advanced fixed tumors in our study group should be taken into consideration.
Even after a full course of preoperative radiotherapy for fixed or tethered rectal cancer, the local recurrence rates remain high, ranging from 16% to 43%.13,14 44 The incidence of local recurrences after resection of fixed tumors was still 38% after combined preoperative radiochemotherapy. ' .R nels). Perfusion might depend on systemic parameters such as heart rate or blood pressure. The complex relations between these parameters and strategies for further improvement of RT/HT will be discussed in a later paper. Patient anxiety, general discomfort, and pain during treatment because of the "hot-spot phenomenon" (specific acute to subacute side effects caused by the electrical interface)32 are problems in the regional HT of deep-seated tumors and are reported to be present in up to 60% of cases.2031 Acute side effects due to regional HT seem to be acceptable regarding grade IM toxicity, yielding rates comparable to the toxicity induced by the other modalities. However, the local increase in electrical field intensity causes an increase in temperature during HT application, resulting in discomfort. Hot spots have been analyzed using model calculations, but they remain very difficult to predict individually.50 The morbidity of combined radiochemotherapy treatment-related toxicity (grade IE) was reported to affect 19% to 69% of the patients.'6'19'5' Some of these patients were treated with large daily fractions (2.5 Gy) without routine use of small-bowel exclusion, and patients with recurrent rectal cancers after abdominoperineal excision were included in the study. Within our group of patients, adding HT did not induce increased grade HI toxicity (14%), and none of the patients experienced grade IV side effects.
The preclinical rationale for HT has been known for a long time. In addition to its cytotoxic and sensitizing effects, other reasons for its effectiveness have recently been discussed. In particular, HT might improve reoxygenation (possibly by raising perfusion), which enhances the effects of radiotherapy.8 This might explain why benefits have been obtained at low temperatures (Tgo 40-40.5 C) unlikely to damage cells under in vivo conditions. It also gives a rationale to apply radiotherapy after heat treatment, as in our study. Vascular breakdown in experimental tumors under HT supported the common practice of applying HT after radiotherapy, because hypoxia might be increased. However, our experience with this group of patients gives evidence of increased perfusion in or at the tumor under HT. Therefore, the optimal sequence of radiotherapy and HT is still an open question.
In conclusion, this phase II study demonstrates that a trimodal therapy regimen with acceptable toxicity can be applied safely in patients with advanced rectal carcinomas. HT was used as part of this regimen and did not increase the side effects of radiotherapy and chemotherapy once the rima ani cooling system was introduced. The resectability rate was good and, except for one patient, all could be resected with curative intent and low perioperative morbidity. The next step in developing thermotherapy might be to reach 120 minutes of cumulative HT at 40.50C or higher in all patients.
Similar to the treatment results in soft-tissue sarcoma,52
HT added to radiochemotherapy in advanced rectal cancer yielded an excellent response of 60%, with 14% histologically proven complete remissions. The true value of HT in this setting, however, will be assessed in a randomized phase III trial that is underway.
